expert reaction to conference abstract from a phase 1 study on safety, tolerability and weight ...
A phase 1 study on Amycretin, a once-a-day weight loss tablet combining GLP-1 and amylin receptors agonists, presented at EASD showed weight reduction and mild to moderate gastrointestinal side effects. Experts highlight the potential of oral medications for obesity treatment, though larger trials are needed to assess long-term effects and compare with injectable drugs.
Reference News
expert reaction to conference abstract from a phase 1 study on safety, tolerability and weight ...
A phase 1 study on Amycretin, a once-a-day weight loss tablet combining GLP-1 and amylin receptors agonists, presented at EASD showed weight reduction and mild to moderate gastrointestinal side effects. Experts highlight the potential of oral medications for obesity treatment, though larger trials are needed to assess long-term effects and compare with injectable drugs.